Biotech IV Monitor

VERA — Vera Therapeutics Inc.

$2.5B market cap · 2 upcoming readouts tracked

Clinical trial readout dates for Vera Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is November 2027.

Next readoutNovember 2027in ~12 months
Upcoming readouts2none in Phase 3
Market cap$2.5B
Cash & investments$384M~4 quarters at last loss rate
Recent 8-K filings1latest 2026-11-05

Upcoming readouts

Phase 2 Atacicept
pMN; IgAN · NCT06983028
November 2027
Recruiting
Phase 2 Atacicept 150 mg
IgA Nephropathy (IgAN); Renal and Urinary Disorders · NCT06674577
May 2031
Enrolling

Cash position

Vera Therapeutics Inc. reported $384M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). Its net loss for that quarter was $94M; at that rate the cash would last about 4 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-05

Companies working on similar indications

Discussion

No messages yet. If you follow VERA, you can start the conversation.
Track VERA in real time
See live implied volatility for VERA and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on VERA
Contact — questions or corrections about VERA: dukeupt@gmail.com